Literature DB >> 9098000

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells.

G Monteleone1, L Biancone, R Marasco, G Morrone, O Marasco, F Luzza, F Pallone.   

Abstract

BACKGROUND & AIMS: Cell-mediated immunity is a feature of Crohn's disease (CD). The heterodimer interleukin (IL)-12, produced by phagocytes, induces T-cell cytokines, primarily interferon (IFN)-gamma. This study examined whether CD lamina propria mononuclear cells (LPMCs) express and release bioactive IL-12.
METHODS: LPMCs were isolated from 13 patients with CD, 9 with ulcerative colitis (UC), and 13 controls. Messenger RNA for p40 and p35 IL-12 subunits was evaluated by reverse-transcription polymerase chain reaction. IL-12 was measured by enzyme-linked immunosorbent assay in LPMC culture supernatants. The INF-gamma-inducing effect of unstimulated LPMC supernatants was evaluated.
RESULTS: Messenger RNA for both IL-12 subunits was detected in LPMCs of 11 of 13 patients with CD, 1 of 9 patients with UC, and 1 of 13 controls (P < 0.001). IL-12 was measured (10.5 +/- 2 pg/mL at 24 hours) in unstimulated CD LPMCs and was enhanced by pokeweed mitogen, lipopolysaccharide, and staphylococcal enterotoxin B. No IL-12 was detectable in 8 of 9 patients with UC and 12 of 13 control-unstimulated LPMCs. IL-12 induced by pokeweed mitogen and staphylococcal enterotoxin B in UC was lower than in CD and did not differ from controls. An IFN-gamma-inducing effect was restricted to unstimulated CD LPMC supernatants and was inhibited by an anti-IL-12 antibody in a dose-dependent fashion.
CONCLUSIONS: IL-12 transcripts are expressed in CD intestinal tissues. CD LPMCs are up-regulated in their capability of releasing bioactive IL-12. Expression and release of bioactive IL-12 seem to differentiate CD from UC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098000     DOI: 10.1016/s0016-5085(97)70128-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  151 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Cytokine mRNA expression in mucosal biopsies from German shepherd dogs with small intestinal enteropathies.

Authors:  A J German; C R Helps; E J Hall; M J Day
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

3.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

4.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

5.  Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration.

Authors:  N Hida; T Shimoyama; P Neville; M F Dixon; A T Axon; T Shimoyama; J E Crabtree
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

Review 6.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

7.  Pre-colectomy appendectomy and risk for Crohn's disease in patients with ileal pouch-anal anastomosis.

Authors:  Zhaoxiu Liu; Haiyan Lu; Ravi P Kiran; Runzhou Ni; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2012-04-24       Impact factor: 3.452

8.  Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.

Authors:  G Docena; L Rovedatti; L Kruidenier; A Fanning; N A B Leakey; C H Knowles; K Lee; F Shanahan; K Nally; P G McLean; A Di Sabatino; T T MacDonald
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

9.  TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis.

Authors:  B Del Zotto; G Mumolo; A M Pronio; C Montesani; R Tersigni; M Boirivant
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.

Authors:  E M Coccia; M E Remoli; C Di Giacinto; B Del Zotto; E Giacomini; G Monteleone; M Boirivant
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.